Prosthesis, usually heart valve, composed of biological material and whose durability depends upon the stability of the material after pretreatment, rather than regeneration by host cell ingrowth. Durability is achieved 1, mechanically by the interposition of a cloth, usually polytetrafluoroethylene, between the host and the graft, and 2, chemically by stabilization of the tissue by intermolecular linking, usually with glutaraldehyde, after removal of antigenic components, or the use of reconstituted and restructured biopolymers.
A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material.
Surgical insertion of synthetic material to repair injured or diseased heart valves.
The valve between the left ventricle and the ascending aorta which prevents backflow into the left ventricle.
The pathologic narrowing of the orifice of the TRICUSPID VALVE. This hinders the emptying of RIGHT ATRIUM leading to elevated right atrial pressure and systemic venous congestion. Tricuspid valve stenosis is almost always due to RHEUMATIC FEVER.
A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.
The plan and delineation of prostheses in general or a specific prosthesis.
Malfunction of implantation shunts, valves, etc., and prosthesis loosening, migration, and breaking.
Pathological condition characterized by the backflow of blood from the ASCENDING AORTA back into the LEFT VENTRICLE, leading to regurgitation. It is caused by diseases of the AORTIC VALVE or its surrounding tissue (aortic root).
The fitting and adjusting of artificial parts of the body. (From Stedman's, 26th ed)
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
Reference points located by visual inspection, palpation, or computer assistance, that are useful in localizing structures on or within the human body.
The valve between the left atrium and left ventricle of the heart.
Removal of an implanted therapeutic or prosthetic device.
Any type of abortion, induced or spontaneous, that is associated with infection of the UTERUS and its appendages. It is characterized by FEVER, uterine tenderness, and foul discharge.
The valve consisting of three cusps situated between the right atrium and right ventricle of the heart.
A conical fibro-serous sac surrounding the HEART and the roots of the great vessels (AORTA; VENAE CAVAE; PULMONARY ARTERY). Pericardium consists of two sacs: the outer fibrous pericardium and the inner serous pericardium. The latter consists of an outer parietal layer facing the fibrous pericardium, and an inner visceral layer (epicardium) resting next to the heart, and a pericardial cavity between these two layers.
Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Backflow of blood from the RIGHT VENTRICLE into the RIGHT ATRIUM due to imperfect closure of the TRICUSPID VALVE.
Pathologic deposition of calcium salts in tissues.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues using a transducer placed in the esophagus.
Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.
Echocardiography amplified by the addition of depth to the conventional two-dimensional ECHOCARDIOGRAPHY visualizing only the length and width of the heart. Three-dimensional ultrasound imaging was first described in 1961 but its application to echocardiography did not take place until 1974. (Mayo Clin Proc 1993;68:221-40)
Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or hematogenously acquired from other sites (late).
Elements of limited time intervals, contributing to particular results or situations.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
A vital statistic measuring or recording the rate of death from any cause in hospitalized populations.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.
The misinterpretation of a real external, sensory experience.
Exclusive legal rights or privileges applied to inventions, plants, etc.

Destructive aortic valve endocarditis from Brucella abortus: survival with emergency aortic valve replacement. (1/643)

Brucella abortus infection of the aortic valve caused acute aortic regurgitation leading to severe left ventricular failure in a 62-year-old man. He made an excellent recovery after emergency aortic valve replacement. This is the third reported case of successful heart valve replacement for Brucella endocarditis and the second such case involving the aortic valve.  (+info)

Long-term survival and valve-related complications in young women with cardiac valve replacements. (2/643)

BACKGROUND: The type of cardiac valve replacement associated with the lowest health risks for young women who may undergo pregnancies is unknown. We investigated which valve type was associated with greatest patient and valve survival and the effect of pregnancy on valve loss. METHODS AND RESULTS: In this retrospective study, all women 12 to 35 years old who underwent valve replacements between 1972 and 1992 at Greenlane Hospital were identified, and follow-up was available in 93%. The 232 women were followed up for 1499 patient-years. Ten-year survival of women with mechanical (n=178), bioprosthetic (n=73), and homograft (n=72) valves was 70% (95% CI, 59% to 83%), 84% (95% CI, 72% to 99%), and 96% (95% CI, 91% to 100%), P=0.002. After adjustment for confounding variables, the relative risk (RR) of death with mechanical compared with bioprosthetic valves was 2.17 (95% CI, 0.78 to 5.88). Thromboembolic events occurred in 45% of women with mechanical valves within 5 years, compared with 13% with bioprosthetic valves, P=0.0001. Valve loss at 10 years was higher in bioprosthetic valves [82% (95% CI, 62% to 92%)] than in mechanical [29% (95% CI, 17% to 39%)] or homograft [28% (95% CI, 12% to 41%)] valves, P=0.0001. Pregnancy was not associated with increased bioprosthetic (RR, 0.96; 95% CI, 0.68 to 1. 35), homograft (RR, 0.65; 95% CI, 0.37 to 1.13), or mechanical (RR, 0.54; 95% CI, 0.27 to 1.08) valve loss. CONCLUSIONS: Although 10-year valve survival was greater with mechanical than bioprosthetic valves, mechanical valves may be associated with reduced patient survival in young women. Thromboembolic complications, often with long-term sequelae, were common with mechanical valves. Pregnancy did not increase structural deterioration or reduce survival of bioprosthetic valves.  (+info)

Haemodynamic performance of aortic pericardial bioprostheses and bileaflet prostheses at rest and during exercise: implications for the surgical management of patients with small aortic roots. (3/643)

OBJECTIVE: To determine the haemodynamic behaviour, at rest and during exercise, of aortic valve pericardial bioprostheses and different sizes of bileaflet prosthesis. DESIGN: Observational study. SETTING: Tertiary medical centre. PATIENTS AND INTERVENTIONS: 74 patients (33 women, 41 men; mean age 64 years) in whom 40 pericardial bioprostheses and 34 bileaflet prostheses sized 19, 21, or 23 mm had been implanted to replace aortic valves. MAIN OUTCOME MEASURES: Doppler echocardiography at rest and at peak exercise, between 12 and 47 months after surgery. RESULTS: All patients achieved a significant increase in heart rate, systolic blood pressure, and cardiac output with exercise. Transvalvar pressure fall, valve area, and left ventricular systolic and diastolic function indices also underwent significant changes with exercise. Reductions in peak and mean transvalvar pressure, at rest and at peak exercise, were greater in patients with small valves (p < 0.05). Valve areas and effective area index were greater in the patients with larger valves (p < 0.001). There were no significant differences between patients with mechanical and biological prostheses with regard to transvalvar pressure fall and valve areas at rest and at peak exercise. CONCLUSIONS: 19 mm and 21 mm aortic prostheses and bioprostheses continue to create significant obstruction, particularly with exercise.  (+info)

The use of a stentless porcine bioprosthesis to repair an ascending aortic aneurysm in combination with aortic valve regurgitation. (4/643)

Over the years, many surgical methods have evolved for the treatment of ascending aortic aneurysm in combination with aortic valve regurgitation; however, precise guidelines for optimal surgical techniques for varying presentations have not been defined. We describe the use of a stentless porcine bioprosthesis (Medtronic Freestyle) in a patient with an ascending aortic aneurysm and aortic regurgitation. We used the complete root replacement method, and anastomosed a Dacron graft (Hemashield) between the bioprosthetic valve and the native aorta to replace the distal part of the aneurysm.  (+info)

Hemodynamic and physical performance during maximal exercise in patients with an aortic bioprosthetic valve: comparison of stentless versus stented bioprostheses. (5/643)

OBJECTIVES: The objective of this study was to compare stentless bioprostheses with stented bioprostheses with regard to their hemodynamic behavior during exercise. BACKGROUND: Stentless aortic bioprostheses have better hemodynamic performances at rest than stented bioprostheses, but very few comparisons were performed during exercise. METHODS: Thirty-eight patients with normally functioning stentless (n = 19) or stented (n = 19) bioprostheses were submitted to a maximal ramp upright bicycle exercise test. Valve effective orifice area and mean transvalvular pressure gradient at rest and during peak exercise were successfully measured using Doppler echocardiography in 30 of the 38 patients. RESULTS: At peak exercise, the mean gradient increased significantly less in stentless than in stented bioprostheses (+5 +/- 3 vs. +12 +/- 8 mm Hg; p = 0.002) despite similar increases in mean flow rates (+137 +/- 58 vs. +125 +/- 65 ml/s; p = 0.58); valve area also increased but with no significant difference between groups. Despite this hemodynamic difference, exercise capacity was not significantly different, but left ventricular (LV) mass and function were closer to normal in stentless bioprostheses. Overall, there was a strong inverse relation between the mean gradient during peak exercise and the indexed valve area at rest (r = 0.90). CONCLUSIONS: Hemodynamics during exercise are better in stentless than stented bioprostheses due to the larger resting indexed valve area of stentless bioprostheses. This is associated with beneficial effects with regard to LV mass and function. The relation found between the resting indexed valve area and the gradient during exercise can be used to project the hemodynamic behavior of these bioprostheses at the time of operation. It should thus be useful to select the optimal prosthesis given the patient's body surface area and level of physical activity.  (+info)

Valve replacement for aortic stenosis in patients with poor left ventricular function: comparison of early changes with stented and stentless valves. (6/643)

BACKGROUND: Long-standing aortic stenosis causes significant left ventricular (LV) dysfunction, which may progress irreversibly. In many cases, LV function can be salvaged by aortic valve surgery, although debate exists regarding the best valve prosthesis to use. METHODS AND RESULTS: We studied 33 patients retrospectively who had significant aortic stenosis and impaired LV systolic function, as assessed by transthoracic Doppler echocardiography. Patients were assessed preoperatively and before discharge from the hospital. A total of 20 patients received a stentless (homograft or Toronto) valve, and 13, a stented valve. No patient had significant aortic regurgitation or other valvular disease. Preoperatively, fractional shortening was 18.8+/-5.5% in the stentless group and 18.6+/-3.8% in the stented group. Postoperatively, it was 25.6+/-6.9% (P<0.001 compared with baseline) and 17.0+/-2.8%, respectively (P<0.001 compared with stentless group). Fractional shortening improved because of a reduction in LV end-systolic and end-diastolic dimensions in the stentless group. Systolic long axis function at the LV free wall also recovered, with an increase in systolic excursion and both peak shortening and lengthening rates. No change was noted in mitral valve Doppler patterns. CONCLUSIONS: Patients who received a stentless valve demonstrated a significantly greater early improvement in LV systolic function compared with those who received a stented valve.  (+info)

Prospectively randomized evaluation of stentless versus conventional biological aortic valves: impact on early regression of left ventricular hypertrophy. (7/643)

BACKGROUND: The aim of this prospectively randomized study was to evaluate left ventricular hypertrophy and its regression after stentless versus conventional biological aortic valve replacement. METHODS AND RESULTS: From March 1996 through April 1998, 180 patients were prospectively selected; 106 patients received a stentless aortic valve (SAV), and 74 received a conventional stented bioprosthesis (CSB). Of these patients, 95% and 96%, respectively, had aortic stenosis. Their mean age was 72.3 and 74.8 years, and there were no significant differences in left ventricular function, preoperative pressure gradients, and NYHA functional status. Aortic annulus diameter indexes were comparable at 13.46 (SAV) versus 13.55 (CSB) mm (P=NS). Larger SAVs were implanted because of the oversizing technique. In-hospital mortality (n=3 and 1 for SAV and CSB) was not valve related. At follow-up, all patients were in NYHA class 1 or 2. Baseline end-diastolic left ventricular posterior wall thickness was 15.6 (SAV) and 14.8(CSB) mm (P=NS) and decreased to 11. 8 (SAV) and 13.2 (CSB) mm (P<0.05) at 6 months. Left ventricular mass index was 213 and 202 g/m(2) at baseline (P=NS), whereas after 6 months, it was 141 (SAV) and 170 (CSB) g/m(2) (P<0.05). CONCLUSIONS: Regression of left ventricular hypertrophy occurs in all patients after aortic valve replacement but is significantly enhanced after SAV implantation. This possibly is due to improved transvalvular hemodynamics.  (+info)

Mid-term comparative follow-up after aortic valve replacement with Carpentier-Edwards and Pericarbon pericardial prostheses. (8/643)

BACKGROUND: The first generation of pericardial valves had a high rate of premature deterioration. The aim of this study was to compare the outcome after aortic valve replacement with second generation pericardial prostheses (Pericarbon and Carpentier-Edwards). METHODS AND RESULTS: Between 1987 and 1994, 162 patients underwent aortic valve replacement with either a Pericarbon (n=81, 69+/-11 years) or a Carpentier-Edwards (n=81, 70+/-11 years) pericardial prosthesis. Mean follow-up was 4.4+/-2.7 years for Pericarbon and 4.8+/-2.4 years for Carpentier-Edwards valves (P=0. 27), giving a total follow-up of 745 patient-years. Thirty-day mortality and 5-year actuarial survival were, respectively, 6.2% and 63.2+/-5.7% in the Pericarbon group and 6.2% and 63.5+/-5.6% in the Carpentier-Edwards group. At 8 years, freedom from (and linearized rates per patient-year) thromboembolism, structural failure, and all valve-related events were, respectively, 91.8+/-3.6% (1.4%), 76. 9+/-8.7% (2.5%), and 58.4+/-9.3% (5.6%) in the Pericarbon group and 94.4+/-2.7% (1%), 100% (0%, P<0.01), and 88.8+/-3.7% (2%, P<0.05) in the Carpentier-Edwards group. There were 9 (11.1%) Pericarbon structural failures related predominantly to severe calcification and stenosis. The actual reoperation rate was 7.4% (1.6% per patient-year) in the Pericarbon group for fibrocalcific degeneration (n=3), periprosthetic leak (n=1), endocarditis (n=1), and aortic dissection (n=1). There was neither structural valve failure nor valve reoperation in the Carpentier-Edwards group. Echocardiographic review of 70 patients from 85 survivors (82.3%) found 4 additional Pericarbon valves with signs of early structural failure but no Carpentier-Edwards valve with such changes. CONCLUSIONS: Eight years after aortic valve replacement, Pericarbon pericardial prostheses compared unfavorably with Carpentier-Edwards pericardial prostheses, with a high incidence of structural valve failure and reoperation.  (+info)

Bioprosthesis has been increasingly implanted for the treatment of transvalvular disease across the world. A new Dafodil™ pericardial bioprosthesis (Meril Life Sciences Pvt. Ltd., India) recently approved by Conformité Européenne (CE) is a tri-leaflet, stented, bovine valve. The purpose of Dafodil-1 first-in-human trial was to evaluate clinical safety and performance (including hemodynamic parameters) of the Dafodil pericardial bioprosthesis in patients who underwent aortic or mitral valve replacement. This prospective, multicenter clinical trial enrolled 60 patients (Aortic: 30 patients; Mitral: 30 patients) from seven sites across India. Safety endpoints were early (≤30 days) and late (| 30 days) mortality and valve-related morbidity. The performance endpoints were hemodynamic performance, improvement in NYHA functional class, and change in the quality of life using SF-12v1 health survey. From July 2017 to July 2018, 60 patients underwent implantation of the Dafodil pericardial bioprosthesis.
TY - JOUR. T1 - Hemodynamic evaluation of 19-mm Carpentier-Edwards pericardial bioprosthesis in aortic position. AU - Takakura, Hiromitsu. AU - Sasaki, Tatsuumi. AU - Hashimoto, Kazuhiro. AU - Hachiya, Takashi. AU - Onoguchi, Katsuhisa. AU - Oshiumi, Motohiro. AU - Takeuchi, Shigeyuki. PY - 2001. Y1 - 2001. N2 - Background. The aortic Carpentier-Edwards pericardial bioprosthesis offers good long-term clinical outcomes with a low rate of structural deterioration. However, little in vivo hemodynamic data is available for this bioprosthesis. Methods. To determine the hemodynamic performance of the 19-mm Carpentier-Edwards pericardial valve, both cardiac catheterization and dobutamine stress echocardiography were electively performed in 10 patients. The mean age at the study was 71.6 ± 4.4 years and the mean body surface area was 1.39 ± 0.11 m2. The peak-to-peak gradient, instantaneous peak gradient, mean gradient, and valve orifice area were measured by standard cardiac catheterization. The ...
Transcatheter aortic valve implantation for failing surgical aortic bioprosthetic valve: from concept to clinical application and evaluation (part 2). JACC Cardiovasc Interv. 2011 Jul; 4(7):733-42 ...
We describe a case of a 76-year old male who presented with progressive dyspnoea. He underwent an aortic valve replacement with a Freedom SOLO bioprosthesis 6 years ago. Transthoracic echocardiography showed a moderate-to-severe leakage of the Freedom SOLO bioprosthesis. During surgical reintervention, a partial tear of the left coronary cusp was seen from the commissure of the right coronary cusp to its base. After radiographic and microscopic examination, no clear cause was found for the failure of this Freedom SOLO bioprosthesis. To our knowledge, this is the third failure of a Freedom SOLO bioprosthesis reported in the literature. When the long-term follow-up of the Freedom SOLO bioprosthesis is available, it has to be compared with other bioprosthesis for long-term durability. ...
TY - JOUR. T1 - Aortic Valve Bioprostheses. T2 - Leaflet Immobility and Valve Thrombosis. AU - Holmes, David. AU - Mack, Michael J.. PY - 2017/5/2. Y1 - 2017/5/2. N2 - Leaflet immobility and valve thrombosis have been reported with both transcatheter and surgical aortic valve bioprostheses. The relationships between these abnormalities and their incidence, time course, clinical significance, predisposing factors, optimal imaging modality, and current therapeutic options remain uncertain but are rapidly evolving. Four-dimensional computerized tomographic imaging has been determined to have the highest sensitivity in studies evaluating leaflet immobility and valve thrombosis. Echocardiography is also used during surveillance, but it appears to be less sensitive. The definitive diagnosis of valve thrombosis is based on a combination of diagnostic 4-dimensional computerized tomographic imaging findings, resolution of imaging abnormalities, and elevated transcatheter gradients with anticoagulation or ...
Title:Prevention of Bioprosthetic Heart Valve Calcification: Strategies and Outcomes. VOLUME: 21 ISSUE: 22. Author(s):L.P. Bre, R. McCarthy and W. Wang. Affiliation:Network of Excellence for Functional Biomaterials (NFB), National University of Ireland, Galway, IDA Business Park, Dangan, Galway, Ireland.. Keywords:Anticalcification, bioprosthesis, crosslinking, glutaraldehyde, heart valve replacement, mineralization.. Abstract:Despite the significant advances in cardiac surgery, heart valve replacement still faces a dilemma. While mechanical valves offer lifelong durability they also commit patients to anticoagulation treatment for the rest of their life. On the other hand, bioprosthetic valves have superior hemodynamic performance but durability of the bioprosthesis limits their use to the elderly, with early onset calcification being the primary cause of biomaterial breakdown. Considering that bioprosthetic valves are not reliant upon anticoagulation, there has been much focus on measures to ...
There has been a trend toward more frequent use of bioprosthetic valves, especially in the young generations, over the last decade.1,2 According to the Society of Thoracic Surgeons database, use of bioprosthetic valve increased from 44% in 1996 to 78% in 2006 in North America.1 Freedom from warfarin use and restrictions on diet and activities make bioprosthetic valves more attractive and popular, and multiple reports have shown that choosing a bioprosthetic valve does not decrease survival despite the increased rate of reoperation.3,4. Article see p 2012. The Mitroflow aortic prosthesis (Sorin Group Inc) is one of the most frequently used bioprostheses, with ,100 000 implanted worldwide.5 The bovine pericardium is mounted externally around the stent, which maximizes the flow relative to the stent size. The valve is placed in the supra-annular position compared with the intra-annular position in some of the other bioprostheses. These characteristics allow superior valve hemodynamics in the ...
Several studies have recognized the high prognostic relevance of achieving an optimal hemodynamic result after aortic valve replacement (1-3,13-16). The presence of severe PPM has been associated with lesser improvement in the functional capacity of the patients (13), lesser regression of LV hypertrophy (14), higher rates of cardiac failure (16), and higher rates of perioperative and long-term mortality (2,3,15,16) after SAVR. The Magna and Freestyle valves are among the most commonly used stented and stentless bioprostheses for SAVR, and the results of valve hemodynamic performance observed in the present study for these 2 types of bioprosthesis were consistent with those of previous studies (17-20), although the aortic annulus and bioprosthesis size were smaller in the present study. Previous studies have also reported that the hemodynamic performance of stentless bioprostheses is generally superior, and accordingly, the prevalence/severity of PPM is lower compared with stented bioprostheses ...
Calcification of glutaraldehyde-preserved bioprosthetic cardiac valves represents a serious clinical problem. Previous work from this laboratory has established the presence in clinical bioprosthetic valve calcifications of vitamin K-dependent calciu
Since the first implant in September 1982, the Medtronic Hancock® II has provided more than 20 years of excellent hemodynamic performance and durability. Design improvements over the past generations include: low profile, flexible stent, Supra-X™ supra-annular placement, T6 anti-calcification tissue treatment, modified fixation process, CINCH® advanced implant system and ULTRA™ minimized sewing ring. Valve sizing is a critical consideration in obtaining optimal hemodynamic performance. This is particular true in small aortic roots. A critical issue is the size of the prosthesis in relation to the patients annulus.. The objective of this clinical study is to evaluate, at six and twelve months, the hemodynamic performance of the HancockÒ Ultra™ bioprosthesis in the aortic position, to analyze the incidence of patient prosthesis mismatch, correlation of gradients, and to ascertain frequency at which a larger valve size is used vs. a patients debrided annulus diameter. ...
Health,...MINNEAPOLIS Nov. 24 /- ATS Medical Inc.(Nas... (Logo: a href http://www.newscom.com/cgi-bin/prnh/20040202/ATSI... The ATS 3f Aortic Bioprosthesis is the Companys first entry into ... The ATS 3f Aortic Bioprosthesis is the only tissue valve that pre...,ATS,Medical,Announces,First,Commercial,Implants,of,the,ATS,3f,Aortic,Bioprosthesis,in,the,United,States,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Between May 1st 1985 and December 31st 1992, 283 Carpentier-Edwards pericardial valves were implanted in 260 patients in the aortic (n = 196), mitral (n = 41) and both aortic and mitral (n = 23) positions at the Gasthuisberg University Hospital in Leuven, Belgium. Patients undergoing tricuspid valve replacement or mixed replacement with another type of prosthesis were excluded from this study. The mean age was 70 +/- 7 years, there were 121 males and 139 females. The mean follow up was 40.55 months, the total follow up experience 10543 months (878.6 patients years). Hospital mortality was 10.4%, and was not significantly related to the position of the valve: 17.3% +/- 7.88% (n = 23) for double valve replacement, 10.2% +/- 2.16% (n = 196) for aortic valve replacement and 7.3% +/- 4.06% (n = 41) for mitral valve replacement. Hospital mortality was 14.1% +/- 3.27% for those with and 7.48% +/- 2.5% for those without concomitant coronary surgery (p = NS). Survival at 92 months was 63% +/- 6% and was ...
A bioprosthetic heart valve comprising leaflets with free edges which do not impinge on adjacent leaflets when the leaflets are closed before being implanted and subject to body fluids and cardiac pressure cycles. Commissures supporting the leaflets have semi-permeable membranes which reduce the pressure load on the leaflets during implantation. In response to immersion in body fluids, the membranes become substantially impermeable. The leaflets can stretch in response to loads and hydration, so that the free edges mate shortly after implantation. First and second mechanisms for supporting leaflets to provide multiple effective spring constants. An inner frame supporting commissures of the valve is elastic, permitting the commissures to bend in toward the center of the prosthetic heart valve at very low loads. A relatively rigid annular support ring supports the elastic frame and provides the second spring constant mechanism. The leaflets have an uncoupled mating edge where the leaflet approach each
Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up) ...
A packaging system is disclosed for shipping a prosthetic tissue valve in a storage solution and preparing and loading of the bioprosthetic valve onto a catheter-based delivery system. The packaging system includes a fluid tight container filled with the storage solution attached to a delivery catheter, wherein the container surrounds the prosthetic tissue valve that is in a pre-loaded position on the delivery catheter during shipment and storage. The prosthetic tissue valve may include an attachment mechanism that attaches to the delivery catheter to properly position the tissue valve for loading within the delivery catheter. In another embodiment where the prosthetic tissue valve is not attached to the delivery catheter during shipment, the attachment mechanism may interact with the prosthetic tissue valve shipping container to prevent the bioprosthetic valve from moving during shipment.
Bioprosthetic valve thrombosis (BPVT) can occur several years after implantation but much earlier than degeneration, stress Sorin V. Pislaru, MD, PhD, and colleagues. The good news, they say, is that cases-once diagnosed-respond well to vitamin K antagonist (VKA) therapy.. The findings are being published in the December 1, 2015, issue of the Journal of the American College of Cardiology.. Raj R. Makkar, MD, of Cedars-Sinai Heart Institute (Los Angeles, CA), lead author of the NEJM paper, told TCTMD in a telephone interview: Clearly weve underappreciated the importance of leaflet thrombosis on structural valve failure, and in a subset of patients this may be the mechanism.. No prospective RCTs have tested the value of anticoagulation in patients with bioprosthetic valves, and studies on both surgical and transcatheter valves would be important, he noted.. Makkar said awareness of these issues is growing in the TAVR field. I think people are serious and people are interested. Everybody ...
TY - JOUR. T1 - Morphological comparison of mitral and aortic bioprostheses explanted from the same patient for primary tissue failure. AU - Pansini, S.. AU - Di Summa, M.. AU - Galloni, M.. AU - Gagliardotto, P.. AU - Parisi, F.. AU - Zattera, G.. AU - Punta, G.. AU - Girotto, M.. AU - Cesarani, F.. PY - 1996/6. Y1 - 1996/6. N2 - Host factors might influence the fate of tissue prostheses. We have analyzed the tissue failure phenomenon in mitral and aortic porcine bioprostheses explanted from the same patient so as to avoid the bias of host factors. The 50 bioprostheses of this study were explanted from 25 patients reoperated on because of malfunctioning due to primary tissue failure. Bioprostheses explanted were photographed, radiographed and observed in polarizing light. All lesions analyzed received a score on the basis of morphological criteria. No difference was observed in the occurrence of pannus, tears or cells infiltrates. Calcifications occurred more extensively in mitral position (p = ...
Price of a print issue €25.00. AIM: The use of synthetic mesh in transplant patients is still under debate. In this paper the authors report their preliminary experience on biological prosthesis for surgical treatment of incisional hernias in transplant patients. MATERIAL OF STUDY: Between 2009-2010, 10 patients with incisional hernia underwent surgery using a biological prosthesis (porcine dermis collagen). All patients were transplanted: 9 kidney transplants and 1 liver transplant. RESULTS: In all patients postoperative course was uneventful and were not observed complications related to surgery, kind of prosthesis or transplanted organs. At follow up, laparoplasty was associated with good functional outcome. DISCUSSION: Transplant patients are at risk for use of synthetic prostheses, as immunosuppressed. In our preliminary experience biological prostheses compared to synthetic ones showed a greater ability to integrate into tissues, to resist bacterial colonization and to reduce cytotoxic ...
The VIV procedure is technically demanding and should be reserved for highly experienced centers. Operators should be skilled in the handling of device malposition, retrieval techniques, and implantation of a second TAVR device, if needed. During screening, the Heart Team must have all of the information about and be familiar with the particular characteristics of the surgical bioprosthesis: the mode of degeneration and echocardiographic parameters (isolated paravalvular regurgitation should be excluded); valve size (most importantly, bioprosthesis internal diameter should be used for TAVR device and size selection; because of better hemodynamic results, CoreValve may be preferred in cases of small bioprosthesis with internal diameter ,20 mm); valve position (intra-annular versus supra-annular); valve type (stented versus stentless); the relation of the bioprosthetic valve to its radio-opaque markers; and the risk for coronary obstruction when VIV is performed inside that specific ...
The valve-in-valve concept is an emerging therapeutic option for patients with degenerative failure of previously implanted xenografts. Reoperation of degenerated bioprostheses has a high mortality risk that increases with the age and associated comorbidities of the patients. The transcatheter valve-in-valve implantation does not need resternotomy or cardiopulmonary bypass, potentially reducing the morbidity and mortality risk. However, unlike the transcatheter implants in native valves, in the valve-in-valve procedures, the leaflets and calcified annulus are replaced with the rigid annulus of the xenograft. This requires accurate sizing of the transcatheter valve, currently available in 2 sizes. Therefore, 3-dimensional imaging techniques, particularly multi-detector row computed tomography (MDCT), may provide a more exact sizing of the host xenograft ring. We report a mitral valve-in-valve procedure in a 79-year-old female patient with previous aortic and mitral valve replacement (a 21-mm and ...
TY - JOUR. T1 - Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis. AU - Petrescu, Ioana. AU - Egbe, Alexander C.. AU - Ionescu, Filip. AU - Nkomo, Vuyisile T.. AU - Greason, Kevin L.. AU - Pislaru, Cristina. AU - Pellikka, Patricia A.. AU - Connolly, Heidi M.. AU - Pislaru, Sorin V.. PY - 2020/3/3. Y1 - 2020/3/3. N2 - Background: Early in the prevention and treatment of bioprosthetic valve thrombosis (BPVT), anticoagulation is effective, but the long-term outcome after BPVT is unknown. Objectives: The goal of this study was to assess the long-term outcomes of patients with BPVT treated with anticoagulation. Methods: This analysis was a matched cohort study of patients treated with warfarin for suspected BPVT at the Mayo Clinic between 1999 and 2017. Results: A total of 83 patients treated with warfarin for suspected BPVT (age 57 ± 18 years; 45 men [54%]) were matched to 166 control subjects; matching was performed according to age, sex, year of implantation, and ...
A new study has found that in patients with failed bioprosthetic aortic valves who underwent transcatheter valve-in-valve implantation, the survival rate was only 83 percent
Bioprosthetic valves are increasingly used in preference to mechanical valves in open SAVR, as lifelong oral anticoagulation is not required and its attendant complications can be avoided. A recent study has shown similar long-term survival rates in patients with bioprosthetic and mechanical valves. However, patients with bioprosthetic valves require reoperations due to their limited durability and expected degeneration;(12) those undergoing such reoperations face increased surgical risk due to their more advanced age (compared with their age during the index SAVR) during the redo surgery and scarring in the non-virgin chest. Consequently, valve-in-valve TAVI appears to be an attractive, minimally invasive method of replacing the degenerated surgical aortic bioprosthesis without the need for a reoperation. Several small case series and a global registry have shown that it is a feasible and viable option for patients at high risk.(5-9). In our initial Asian experience of valve-in-valve TAVI in ...
Fingerprint Dive into the research topics of Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Together they form a unique fingerprint. ...
Methods and results Preoperative echocardiography and dobutamine stress echocardiography at 1 year postoperatively were undertaken in 106 patients (n=18-24 from each group). Stentless bioprostheses, whether porcine or bovine, displayed superior haemodynamics across nearly all echocardiographic parameters: lower gradients, larger effective orifice area, higher dimensionless severity index (DSI) and lower resistance, when compared with stented or mechanical prostheses. Comparing both stented designs, bovine tissue performed the worst at rest, but with stress, there was no difference. The stress performances of the stentless bioprostheses were similar to the mildly stenosed native aortic valve, whereas the performances of the stented and mechanical prostheses resembled that of native valves with mild-to-moderate stenoses. Haemodynamic differences, however, did not translate into differences in left ventricular mass reduction at 1 year.. ...
Sorin Group (Milan, Italy) has been awarded CE mark approval for the Solo Smart, a stentless aortic valve implant. Like its predecessor, the Freedom Solo v
CARDIOTHORACIC ANESTHESIOLOGY: Clinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by Four-Dimensional Computed Tomography is organized by The Society of Thoracic Surgeons (STS).
Surgical Bailout Therapy after Implantation of a Medtronic CoreValve Bioprosthesis. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
We carefully read the recent paper by Hammond et al. (1) on the use of sutureless bioprosthetic valve for homograft failure in the setting of infective endocarditis (IE). This article is the latest demonstration that new sutureless and rapid deploymen
When facing heart valve replacement surgery, its important to understand the available options. Check out this blog post to learn more!
A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. The high elastin-containing biomaterial is further characterized by having anisotropic properties wherein the biological material has a greater stiffness in one direction and a greater elasticity in a cross direction. For instance, the biological material has an elastin content of about 30% by weight. In one embodiment, the biological material is vena cava tissue.
Results In patients with VHD, rivaroxaban was associated with more ICH and major bleeding than other NOACs, while edoxaban 30 mg was associated with least major bleeding. Data combining all NOACs showed a significant reduction in SSE, MI and ICH (0.70, [0.57 to 0.85; p,0.001]; 0.70 [0.50 to 0.99; p,0.002]; and 0.46 [0.24 to 0.86; p,0.01], respectively). Analysis of 280 patients with AF and a BPHV showed similar outcomes with NOACs and warfarin. ...
Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12 C. to 30 C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint ...
Mayos structural heart team provides comprehensive care to patients who have previously undergone surgery to replace the mitral or tricuspid valve with a tissue bioprosthesis. Existing dysfunctional bioprosthetic valves can be
Brief summary: aortic bioprostheses. Indications: For use in patients whose aortic valvular disease warrants replacement of their natural or previously placed prosthetic valve.. Contraindications: Do not use if surgeon believes it would be contrary to the patients best interests.. Complications and side effects: Stenosis, regurgitation, endocarditis, hemolysis, thromboembolism, valve thrombosis, nonstructural dysfunction, structural valve deterioration, anemia, arrhythmia, hemorrhage, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, angina, any of which could lead to reoperation, explantation, permanent disability, and death.. Warnings: Alternative therapies should be considered in the presence of conditions affecting calcium metabolism or when calcium containing chronic drug therapies are used, including children, adolescents, young adults, and patients on a high calcium diet or maintenance hemodialysis. Should be used with caution in the presence of severe ...
November 27, 2007 - St. Jude Medical Inc. announced FDA approval of its Epic Stented Tissue Valve with Linx AC Technology. The Epic Valve, which is identical in design to the companys Biocor Valve, also incorporates patented anti-calcification technology designed to protect against tissue mineralization, or hardening.. An estimated 100,000 Americans undergo heart valve replacement annually and the majority of them receive tissue valves. Valve durability is affected by both mechanical stress and tissue calcification. The Epic Valve is designed to address both issues to deliver long-term performance.. The Epic Valve sets a new standard for addressing tissue mineralization and potentially extending long-term valve durability, said Vibhu Kshettry, M.D., director of Cardiac Surgery at the Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, and a principal investigator in the Epic clinical study. Enhanced durability, combined with a design that facilitates the implant ...
The Bioprosthesis Valves market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
OBJECTIVES: The aim of this study was to evaluate the hemodynamic performance of a sutureless bioprosthesis under high workload at mid-term follow-up. METHODS: Thirty-two patients who underwent isolated aortic valve replacement with a Perceval sutureless bioprosthesis with a minimum follow-up of 1 year were enrolled in this study. S size prosthesis was deployed in 10 patients (31.3%), M size in 9 (28.1%), L size in 8 (25%) and XL size in 5 (15.6%). Effective orifice area (EOA), EOA index (EOAi), and transvalvular gradients were assessed at rest and during dobutamine stress echocardiography (DSE) a median of 19 ...
Professional information on Medtronics Hancock® Bioprosthetic Valved Conduits for use in reconstructive procedures for the repair of congenital or acquired cardiac and great vessel malformations or pathology.
A system for treating a vascular condition includes a conduit having an inner wall and at least one locking member positioned within the inner wall of the conduit. The system also includes a stented valve positioned in contact with the locking member within the inner wall of the conduit. A method for treating a vascular condition includes inserting a conduit with a stented valve into a target region of a vessel, positioning a contact portion of the stented valve against a locking portion of the conduit and preventing migration of the stented valve within the conduit based on the positioning.
A system for treating a vascular condition includes a conduit having an inner wall and at least one locking member positioned within the inner wall of the conduit. The system also includes a stented valve positioned in contact with the locking member within the inner wall of the conduit. A method for treating a vascular condition includes inserting a conduit with a stented valve into a target region of a vessel, positioning a contact portion of the stented valve against a locking portion of the conduit and preventing migration of the stented valve within the conduit based on the positioning.
Diagnosis Code T82.223S information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Continuous improvement in the mechanics, preservation and anticalcification treatment made bioprostheses the standard mode of valve replacement in the aging population. A novel Support System with large openings at the Commissural posts has been developed and the performance and durability of bioprostheses constructed went under evaluation. … Heart valve pulse duplicator. A heart valve pulse duplicator Vivitro SPS3891 (Vivitro Systems Inc., Victoria, BC Canada) was used to measure hemodynamic parameters. All tests were performed with the standard FDA waveform …. Go to the Article ...
Diagnosis Code T82.222S information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Source: ISTAT 2001: At the beginning of 2011, there were 608,493 people residing in Genoa, of whom 47% were male and 53% were female. PubMed Central. PubMed Central. For the period before ICD-10 implementation (1970-2002) and when Istat data (2004-2005) are lacking, mesothelioma deaths were estimated through statistical models (logistic, Poisson). Cox, Dana C.; Edwards, Michael Todd. Utility of a point-of-care device for rapid determination of prothrombin time in trauma patients: a preliminary study. The opening lines of How the Grinch Stole Christmas! EFFECTS OF CYCLIC FLEXURAL FATIGUE ON PORCINE BIOPROSTHETIC HEART VALVE HETEROGRAFT BIOMATERIALS. > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > Per quanto riguarda la richiesta di uno studio epidemiologico descrittivo, la informo, sempre la Cimini scrive a me, che le cause di morte della popolazione di ogni comune ...
Figure 2. Because of the surgical risk of a second thoracotomy, a logistic EuroSCORE of 7.14%, and associated comorbidity, a repeat operation was ruled out, and treatment by percutaneous implantation of a CoreValve aortic prosthesis was decided. The operation was successfully completed using local anesthesia and light sedation. A 29-mm CoreValve aortic prosthesis was implanted without complications through a femoral artery approach. The gradient peak disappeared (Figure 2B) and follow-up echocardiography showed perfect valve functioning (Figure 3A and B) with minimal regurgitation (Figure 3C). The patient was discharged 6 days after the procedure, with improved symptoms and a reduction of NTProBNP concentration from 2561.3 to 187.6 pg/ mL. At 8 months of follow-up, the patient was asymptomatic.. ...
TY - JOUR. T1 - Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis. AU - Chamsi-Pasha, Mohammed A.. AU - Alyousef, Tareq. AU - Sayyed, Samer H. PY - 2014/1/1. Y1 - 2014/1/1. N2 - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly limited. We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy. (Echocardiography 2014;31:E278-E281).. AB - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly ...
TY - JOUR. T1 - Detection, localization, and quantitation of bioprosthetic mitral valve regurgitation. An in vitro two-dimensional color-Doppler flow-mapping study. AU - Vandenberg, B. F.. AU - Dellsperger, K. C.. AU - Chandran, K. B.. AU - Kerber, R. E.. N1 - Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 1988. Y1 - 1988. N2 - The usefulness of two-dimensional color-Doppler flow-imaging (2D Doppler) in the detection, localization, and quantitation of bioprosthetic mitral valve regurgitation is uncertain. Mitral bioprostheses, before and after the creation of transvalvular (n = 33), paravalvular (n = 17), or combined (n = 23) defects, were mounted in a pulsed duplication system (flow rates, 2.5-6.5 l/min; pulse rate, 70 beats/min). An Aloka 880 2D Doppler system (Japan) was used to image the regurgitant jets in the simulated left atrial chamber, analogous to images obtained with transesophageal echocardiography. Jet area was corrected to an estimate of stroke volume: 2D ...
The perfect heart valve substitute has not yet been developed and matching the patient to existing options to optimize survival and reduce valve-related complications remains challenging. The choices for aortic valve replacement (AVR) are mechanical valves, bioprosthetic valves, and biological valves such as aortic valve homograft and the Ross procedure (pulmonary autograft). The latter is a complex operation because it transfers the patients own pulmonary valve into the aortic position and uses a biological valve to replace the pulmonary valve, transforming a single-valve disease into a 2-valve disease. These considerations are not important to most North American patients who undergo AVR because they are older and the durability of bioprosthetic valves in this age group is excellent (1,2). The risk of bioprosthetic valve failure 20 years after AVR is ,10% in patients 70 years of age and older (1,2). A report based on the Society of Thoracic Surgeons Database from January 1997 to December 2006 ...
The Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve system is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.. The Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve system is indicated for patients with symptomatic heart disease due to failing (stenosed, insufficient, or combined) of a surgical or transcatheter bioprosthetic aortic valve or surgical bioprosthetic mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).. Contraindications (Who should not use): ...
No survival difference was observed between use of mechanical and bioprosthetic mitral valves in patients aged 50-69 years matched by propensity score (actuarial 15-year survival 57.5% [95% confidence interval (CI) 50.5-64.4%] vs. 59.9% [95% CI 54.8-65.0%], hazard ratio [HR] 0.95 [95% CI 0.79-1.15]), or in a subgroup analysis of age by decade. Among patients matched by propensity score, mechanical versus bioprosthetic mitral valve replacement was associated with higher 15-year incidence of stroke (14.0% [95% CI 9.5-18.6%] vs. 6.8% [95% CI 4.5-8.8%], HR 1.62 [95% CI 1.10-2.39]) and bleeding events (14.9% [95% CI 11.0-18.8%] vs. 9.0% [95% CI 6.4-11.5%], HR 1.50 [95% CI 1.05-2.16]), but a lower incidence of reoperation (5.0% [95% CI 3.1-6.9%] vs. 11.1% [95% CI 7.6-14.6%], HR 0.59 [95% CI 0.37-0.94]).. ...
Subclinical leaflet thrombosis occurred frequently in bioprosthetic aortic valves, more commonly in transcatheter than in surgical valves. Anticoagulation (both NOACs and warfarin), but not dual antiplatelet therapy, was effective in prevention or treatment of subclinical leaflet thrombosis. Subclinical leaflet thrombosis was associated with increased rates of TIAs and strokes or TIAs. Despite excellent outcomes after TAVR with the new-generation valves, prevention and treatment of subclinical leaflet thrombosis might offer a potential opportunity for further improvement in valve haemodynamics and clinical outcomes.. ...
A method is provided for implanting a valve having at least one valve leaflet within the cardiovascular system of a subject. One step of the method includes preparing a substantially dehydrated bioprosthetic valve and then providing an expandable support member having oppositely disposed first and second ends and a main body portion extending between the ends. Next, the substantially dehydrated bioprosthetic valve is attached to the expandable support member so that the substantially dehydrated bioprosthetic valve is operably secured within the main body portion of the expandable support member. The expandable support member is then crimped into a compressed configuration and placed at a desired location within the cardiovascular system of the subject. Either before or after placement at the desired location, fluid or blood re-hydrates the substantially dehydrated bioprosthetic valve.
PhD Student Position in Mechanisms of Laminar-Turbulent Transition Past Bioprosthetic Aortic Valves The ARTORG Center for Biomedical Engineering Research is th
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval® Plus sutureless surgical aortic heart valve is now available for commercial release in Europe, having successfully completed a one-year limited launch with initial real-world clinical data gathering. Perceval Plus is positioned to become an essential component to any comprehensive heart program. Building on the clinically proven experience with Perceval®, this next-generation valve facilitates minimally invasive cardiac surgery (MICS) and makes sutureless aortic valve replacement available to a wide patient population. Key innovations with Perceval Plus include the anticalcification treatment, FREE, for valve durability, along with design changes intended to improve patient outcomes.
Copyright in the material you requested is held by the American Society of Mechanical Engineers (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to the American Society of Mechanical Engineers Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to the American Society of Mechanical Engineers Privacy Policy for further information ...
Betsy Evans of Leeds General Infirmary in the United Kingdom presents a discussion on TAVI and surgery for prosthetic valve failure. She discusses the background of biological valve implant rate, rate of TAVI, and structural valve deterioration and treatment options. She focuses on two treatment techniques: redo AVR surgery and the TAVI valve-in-valve procedure.. ...
0067] In the embodiments described above relative to FIGS. 7 and 8, the tubular valve segments of stented valves of the invention have a ring of pericardial material that is thicker at one or both of its ends where the material is rolled or folded back on itself. This rolled-back material can overlap or cover the edge of the stent, such as to cover the edge of the stent wires, thereby making the edge or edges of the stented valve smoother. Alternatively, the material may be rolled or folded back in such a way that it does not cover the edge of the stent. For example, a folded portion of material can be positioned so that it is adjacent to an end of a stent and/or the folded portion of material can be positioned to face the interior opening or portion of the stent. In any case, the extra thickness of the material can be beneficial to prevent the stented valve from leaking around its perimeter when implanted in a patient. That is, the rolled or folded areas can help to stabilize the stented valve ...
The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU ...
For aortic root replacement in annuloaortic ectasia (AAE), an artificial prosthesis is commonly sutured to the aortic annulus (hemodynamic ventriculoaortic junction). We consecutively had 6 cases of aortic root replacement using anatomic ventriculoaortic junction suture. This anatomic ventriculoaortic junction suture is a simplified and practical method for aortic root replacement in the same way as using stentless bioprostheses or homografts ...
For the foreseeable future, bioprosthetic heart valves (BHV) fabricated from xenograft biomaterials will remain the dominant replacement prosthetic valve design...
Since the introduction of the sutureless Perceval® (Sorin Group, Saluggia, Italy) in Europe after CE mark in 2012, the sutureless approach is becoming more and more popular. Sutureless implantation in general is easy, fast and safe, but bears several potential pitfalls. This might result in inferior functional results affecting also clinical outcomes. In our center, more than 300 implant procedures have been performed up to date by mainly two senior surgeons. The technique is in the process of spreading to all surgeons performing aortic valve procedures. Proctored activities are completed at our and other institutions, and wetlab activities are conducted in collaboration with the manufacturers research and development laboratory. This article was written to give a step-by-step advice for surgeons who want to start a sutureless program or even have made limited experience with this approach wanting to reconfirm their technique. The focus is kept on surgical aspects regarding indication, ...
In terms of complications, Chhatriwalla said concerns have been raised about injuring the aorta or rupturing the annulus, though so far these have not been seen. Its also possible that BVF might increase the risk of thromboembolic events, though it might be hard to tease out the mechanism by which they occur, he said.. But there are ways to mitigate risks, Chhatriwalla stressed, such as by timing BVF differently.. Some operators favor doing BVF ahead of TAVR, he said. The thought behind this is that the size of the new TAVR valve is selected with the knowledge of whether or not the bioprosthetic valve can be fractured in the first place. So you fracture the valve first, you have success, and then put in maybe a larger-sized [TAVR] valve as a result, he explained.. But he and others at Saint Lukes prefer doing it after the TAVR device is implanted, Chhatriwalla added. Our mindset [is] were going to put in the valve size thats warranted, and were going to check the hemodynamics. Then if ...
The Carpentier-Edwards Bioprosthetic Valved Conduit (Model 4300) is made from a porcine (pig) aortic valve that has been preserved and mounted on a flexible frame. The flexible frame is composed of a corrosion resistant cobalt chromium metal alloy, silicone rubber, and is covered with polytetrafluoroethylene (PTFE) cloth. The valve is then mounted in a polyester tube. This device can be used to create an extra-cardiac pathway for blood flow in the pulmonic position. This conduit was introduced in the 1970s. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
AIM: Postoperative renal dysfunction after aortic valve replacement is a serious complication. To minimize its occurrence, risk factors have to be identified, and if possible eliminated. METHODS: Of 1000 consecutive patients, who underwent AVR, a file study was performed chi(2)nd logistic regression analysis were performed to study the effect of 24 preoperative, 7 peroperative and 7 postoperative factors on the occurrence of 30-day postoperative worsening of renal function. RESULTS: Fifty-three patients had a 30-day postoperative decrease of renal function. Nine of these patients died, which is significantly more than the mortality without this complication ( ...
Fatigue and Biodegradation in Engineered Tissue Devices: At present, about half of all heart valve replacements incorporate tissue-derived components: either transplanted human valves or so-called bioprostheses incorporating chemically-treated porcine or bovine tissues. While tissue valves offer more physiological blood flow and freedom for the patient from significant anti-clotting drugs, these valves typically fail in under 15 years. It has been estimated that more than 90% of all failed tissue valves show tears and perforations in the tissue leaflets; moreover, there is strong pathological evidence that host inflammatory cells are present at the margins of such damage. We are using a unique combination of mechanical fatigue simulation, proteolytic enzymes, and macrophage culture to look at the mechanisms by which engineered tissue valves fail. Weve shown a synergy between fatigue damage to collagen bundles and enzymatic cleavage (that is, the two acting together are more damaging than the ...
Health,... - Offers New Payment Options (10-Pay 15-Pay or 20-Pay) - O... Policies ... - Easy to illustrate sell and service ...BOSTON May 6 /- John Hancock has launched ane...,John,Hancock,Launches,New,Fully,Guaranteed,Whole,Life,Insurance,Product,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
One Piece Hentai with Boa Hancock | Toon sex pic ##00013059694 female ariyon aryion awaiting ejaculation boa hancock breasts censored group sex highres long hair nipples nude one piece very long hair
Discover the best homework help resource for HUM SRVS at Allan Hancock College. Find HUM SRVS study guides, notes, and practice tests for Allan Hancock College.
Hancock county, Kentucky Plants Allergy Info for Research - Complete Online Significant Allergens and Plants Reference for Hancock county in Winter
Hancock county, Ohio Plants Allergy Info for Research - Complete Online Significant Allergens and Plants Reference for Hancock county in Winter
Turkeys Istanbul International Jazz Festival has landed a pair of firsts - Paul Simon will make his first appearance in the country when he closes the event next month (Jul11) and Herbie Hancock will debut his Tribute To Miles show.The...
The Hancock Inn in Hancock, New Hampshire, is one of the oldest inns in New England and home to the delicious Fox Tavern.  Whether you are skiing at Crotched Mountain or a history buff, this quaint bed and breakfast is a must-see. 
Volunteer with Hancock County Habitat for Humanity. Find Hancock County Habitat for Humanity volunteering opportunities at VolunteerMatch!
Escucha las previsualizaciones de las canciones del álbum Orchestra - Single, y enterate de las ultimas novedades de tu artista Phil Hancock (2015) - 375 - freeiplus.com - Publicado: 2015-11-23 - ℗ 2015 Phil Hancock
Want an ad-free experience?Subscribe to Independent Premium. Inside Politics: All adults vaccinated by autumn, says Matt Hancock, Seven mass vaccination centres open across England, Populist propaganda is damaging the rollout of Covid vaccines, Unions urge public to back decent pay rise for NHS workers, Covid patients occupying more than 30,000 hospital beds in England, Increased restrictions would be tough - but the alternative is worse, Tony Blair advising Matt Hancock on pandemic response, Tougher lockdown not ruled out by Matt Hancock, UK ramps up vaccine rollout, targets every adult by autumn, Government pushes ahead with controversial rapid testing programme, UK to vaccinate out of pandemic by looking to local GPs, Inside Politics: Boris Johnson turns on completely wrong Trump, Covid vaccine will not stop hospitalisations, warns Hancock, Matt Hancock says he is not aiming for a zero-Covid Britain, Australian PM suggests UK cutting corners with Covid vaccine, Live: PM announces ...
Portage Health Hospital of Hancock, MI ratings and quality report. Compare Portage Health Hospital to other nearby hospitals in Michigan.
Much has changed in the 21 years since Donna Zirkles physician found a lump during her annual breast exam.. The diagnostic mammogram that followed came back negative. Fortunately, Donnas doctor didnt stop there.. Bless my doctor, Donna said. She called me back and said, Donna, I know theres a lump there. Would you please go get an ultrasound? I actually thought about not doing that, but I trusted her. So, I went for the ultrasound, and I saw it on the screen-a little bitty thing.. Donna is one of a small number of patients - fewer than 10% - who receive a false negative from a mammogram. Her family physician sent her to see Cam Gabrielsen, then the breast surgeon at Hancock Health. Even Dr. Gabrielsen had his doubts about whether the 1.3cm tumor was cancerous.. I had a lumpectomy, Donna said. I hadnt signed off for a mastectomy, because they didnt think it was going to be cancer.. It was. And, three weeks later, she ended up having the mastectomy.. It turns out Donnas cancer was ...
Matt Hancock brings rare digital experience to running the NHS and social care systems, but can he overcome the legacy of past health service technology failures?
Dr. Michael Carter, MD is a Orthopedic Sports Medicine Surgery Specialist in Hancock, MI. He is affiliated with UP Health System - Portage. He is accepting new patients. Be sure to call ahead with Dr. Carter to book an appointment.
David F. DAlessandro was named president and chief operations officer of John Hancock Mutual Life Insurance. The promotion of the unconventional insurance executive signifies the industrys push to redefine itself.
Vanderbilt-Ingram Cancer Center and the Vanderbilt Institute of Chemical Biology developed out of the work of the Hancock Lab to merit national acclaim for cancer care and translational research that moves discovery from the lab to benefit patients. Today Vanderbilt-Ingram discoveries in cancer genetics are saving lives through precision cancer medicine that precisely targets therapy based on tumor characteristics for patients with melanoma and cancers of the lung, colon and breast. More potent cancer medicines are on the horizon as Vanderbilt-Ingram researchers identify promising candidates by designing novel molecules that effectively inhibit notoriously undruggable mutations found commonly in many cancers and drug-resistant tumors. This research could ultimately lead to treatment for many different types of cancer.. These groundbreaking innovations testify to the wonderful impact achieved by a remarkable family and friends working closely with Vanderbilt scientists. Their collective ...
IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF ALABAMA NORTHERN DIVISION DAVID HANCOCK, Plaintiff, v. JAMES HOOD, et al., Defendants. ) ) ) ) ) ) ) ) ) CIVIL ACTION 2:09-00026-KD-N JUDGMENT In accordance with the Order entered this date, it is ORDERED, ADJUDGED and DECREED that plaintiffs federal claims are DISMISSED with prejudice and that supplemental jurisdiction over the state-law claim under the Alabama Medical Liabilities Act, Ala. Code 6-5-484 (1975) asserted in Count Five of the Third Amended Complaint is hereby DECLINED and Count Five is DISMISSED without prejudice. Thus, it is ORDERED, ADJUDGED and DECREED that this action is DISMISSED in its entirety. DONE and ORDERED this 18th day of February, 2010. s/ Kristi K. DuBose KRISTI K. DuBOSE UNITED STATES DISTRICT JUDGE ...
278 ALLAN HANCOCK PACIFIC EXPEDITIONS VOL. 3 D. 138, dredged in 30 m., south of Tiburon Island, near Turners Island, Jan.; D. 347, in 22 m., off Punta Penasco, Feb. This species is distinct from Halymenia abyssicola of this paper in its thinner fronds (70-130 ft), outer cortex of only one or two layers of small cells, and absence of a thick surface jelly. Halymenia ? abyssicola sp. nov. Frondes planae membranaceae, minime 8 cm. latae, 300 [i crassae, marginibus integris, atro-roseae; glutino superficial! 25-35 p, crasso; corticibus stratis paucis cellularum minutarum dense aggregatarum, 5-7 u, diam. compositis; subcorticibus cellulis majoribus compositis; in medulla filamentis laxe intricatis et crabro con- junctiones stellae-formantes ostendentibus; (frondibus fructuosis nondum visis). Fronds plane, membranous, basal parts unknown, at least 8 cm. broad, with an entire margin, 300 ft thick, deep rose colored; cross section showing a thick surface jelly 25-35 ft thick, a cortical tissue of a few ...
I saw this piece by journalist and former Cameron-Levita speechwriter Ian Birrell, sometimes seen on the TV newspaper reviews: https://inews.co.uk/opinion/one-nation-toryism-has-died-a-brutal-death/ Ian Birrells view of Matt Hancock It would be a brave person who picked out the politician that has most debased themselves since the Brexit debacle exploded. But among the favourites in this crowded field…
E William Hancock is on CAP Network. CAP Network is a virtual workspace, to support collaboration among faculty, graduate students, postdocs and staff.
He was in Washington D.C. and inaugurated as Americas first president in 1789 when the Hancock Inn opened its doors. This room with a double bed and an inviting window seat alcove, overlooking the backyard, is a cozy retreat for a couple or single traveler. It is a perfect space for those who know how to travel light. There is a full bath with shower/tub combination.. ...
Five students from Allan Hancock College will travel to Louisville, Ky., to compete in the SkillsUSA National Championships, which aim to recognize st...
Corporate actions such as M&As come with multiple implications for your retirement plans. Let John Hancock can help you plan for the coming changes.
Buy Billy Hancock - Out of the Darkness [CD] at DeepDiscount.com. Music: Folk: 791022261127. Guaranteed Lowest Price. Free Shipping on Orders over $25!
Herbie Hancock  70th birthday bash  Carnegie Hall Bill Cosby  saxophonist Joe Lovano  trumpeter Terence Blanchard  saxophonist Wayne Shorter Miles Davis\\ 1960s quintet...
2001). "Midterm evaluation of the Tissuemed (Aspire) porcine bioprosthesis: 493 patients, 506 bioprostheses". The Annals of ... 2003). "Ten year experience with Aspire (Tissuemed) porcine bioprosthesis: single centre experience". Cardiovascular Surgery. ...
In this category we find examples such as animal tissue prostheses (xenogeneic bioprosthesis). Xenogeneic heart valves are of ... "In vitro testing of bioprostheses: influence of mechanical stresses and lipids on calcification". The Annals of Thoracic ...
Great damage can be inflicted on a bioprosthesis at the time of its implantation. One of the not so rare causes is allowing the ... Watanabe describes a case of an Ionescu-Shiley bioprosthesis which functioned 24years in the mitral position of a patient. The ... Macro and microscopic pathology studies of failed porcine bioprostheses by Schoen and Cohn showed in detail the process of ... Concerning the surgeon: Correct rinsing of the bioprosthesis prior to implantation, maintaining the moistness of the valve ...
Tricuspid valve replacement using either a mechanical prosthesis or a bioprosthesis may be indicated. (Mechanical prostheses ... may cause thrombo‐embolic phenomena, bioprostheses may have a degeneration problem). Some evidence suggests that there are no ...
"Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses". N Engl J Med. 324 (9): 573-579. ...
"Primary safety and effectiveness feasibility study after surgical aortic valve replacement with a new generation bioprosthesis ...
"Tropheryma whipplei Infection of an acellular porcine heart valve bioprosthesis in a patient who did not have intestinal ...
"Primary safety and effectiveness feasibility study after surgical aortic valve replacement with a new generation bioprosthesis ...
... surgery is the replacement of one or more of the heart valves with either an artificial heart valve or a bioprosthesis ( ...
... bioprosthesis MeSH E07.695.110 - blood vessel prosthesis MeSH E07.695.120 - bone nails MeSH E07.695.125 - bone plates MeSH ...
... and developed and implanted the first ASEAN bioprosthesis, the PHCA porcine valve. The first patient to be admitted to the PHC ...
Carpentier-Edwards Pericardial Bioprosthesis.' This valve is reported to perform better than its predecessor, the original ...
Also, its possible that many patients in the Brazilian trial received their bioprosthesis because of rheumatic valvular ...
A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved ... The tissue of the present invention can generally be utilized in any of a number of bioprostheses. For instance, bioprostheses ... The present invention is generally directed to improved bioprostheses and methods for forming the improved bioprostheses. In ... bioprostheses are disclosed including tissues which have a greater elastin content than tissues used in similar bioprostheses ...
Information for healthcare professionals about the Avalus Bioprosthesis Pericardial Aortic Surgical Valve for the treatment of ...
A composite Dacron graft, which includes the new valve bioprosthesis or prosthesis, is put in place. Then, the coronary ...
The primary objective of the study is the hemodynamic performance of the bioprosthesis at 6 and 12 months after surgery. [ Time ... Hancock II Ultra Porcine Bioprosthesis Hemodynamic Study. This study has been completed. ... bioprosthesis in the aortic position, to analyze the incidence of patient prosthesis mismatch, correlation of gradients, and to ...
Mitroflow aortic bioprosthesis 5-year follow-up: North American Prospective Multicenter Study. Ann Thorac Surg. 2012;94:1198- ... Early Structural Valve Deterioration of the Mitroflow Aortic Bioprosthesis. Tsuyoshi Kaneko, Igor Gosev, Marzia Leacche, John G ... The valve is placed in the supra-annular position compared with the intra-annular position in some of the other bioprostheses. ... Alvarez et al11 reported their series of 491 patients ,70 years of age who received a Mitroflow aortic bioprosthesis. Freedom ...
Aortic Bioprosthesis. ATS Medical acknowledged the positive clinical results of aortic root dimensions study presented by noted ... Louis, Missouri, and principal in the development of the ATS 3f(R) Aortic Bioprosthesis offered his comments on Dr. Jins ... Aortic Bioprosthesis with its single suture line/3 tab fixation, stentless valves implanted with conventional double suture ...
Subclinical Aortic Valve Bioprosthesis Thrombosis Assessed With 4D CT (SAVORY). The safety and scientific validity of this ... Subclinical Aortic Valve biOprosthesis thRombosis Assessed With 4D Computed tomographY Imaging. Study Start Date :. April 2015 ... Frequency of patients with abnormal aortic valve bioprosthesis leaflet mobility and morphology [ Time Frame: At least 21 days ... The frequency of this potentially ominous phenomenon on both transcatheter and surgical aortic valve bioprosthesis is unknown, ...
When the long-term follow-up of the Freedom SOLO bioprosthesis is available, it has to be compared with other bioprosthesis for ... Patients with TF bioprostheses had higher rates of prolonged mechanical ventilation, whereas patients with the FS bioprosthesis ... Before matching, severe thrombocytopenia (Solo bioprosthesis and 1% with a Perimount bioprosthesis (p Solo (p Solo and ... Case 1: patients with bioprosthesis dysfunction; Case 2: severe aortic stenosis; Case 3: dysfunction of aortic bioprosthesis. ...
... has determined the regulatory review period for EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS (Models 11000A and 11500A) and is ... EDWARDS PERICARDIAL AORTIC Start Printed Page 47962BIOPROSTHESIS MODEL 11000A and MODEL 11500A are indicated for the ... Determination of Regulatory Review Period for Purposes of Patent Extension; Edwards Pericardial Aortic Bioprosthesis. A Notice ... FDA has determined that the applicable regulatory review period for EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS is 1,858 days. Of ...
The Toronto Root bioprosthesis is safe and provides good clinical and hemodynamic function after full root replacement with or ... The Toronto Root bioprosthesis with BiLinx anticalcification treatment (St. Jude Medical, St. Paul, MN) was introduced into ... received full root replacement at our institution with the Toronto Root bioprosthesis from June 2001 until November 2007. The ...
Aortic Bioprosthesis Structural Valve Dysfunction Other: 18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT Phase 4 ... Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD) (TEP-SVD). The ... Both 18F-Fluoride and 18F-FDG TBR will be correlated with bioprosthesis calcium scoring and the following echocardiographic ... SVD defined on echocardiography by an alteration of bioprosthesis leaflets function with a mean transvalvular gradient , 20 ...
... on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis ... Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis. ... 1.4 Transapical transcatheter mitral valve‑in‑valve implantation for a failed surgically implanted mitral valve bioprosthesis ... valve implantation for a failed surgically implanted mitral valve bioprosthesis onto the National Institute for Cardiovascular ...
Percutaneous Tricuspid Valve Replacement Using a Valved Bioprosthesis Tratamiento percutáneo de la insuficiencia tricuspídea ...
One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry. The European ... Methods and Results-The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial ... One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry ... One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry ...
... valve-in-valve procedure with a CoreValve prosthesis for the treatment of a severely stenotic degenerated aortic bioprosthesis. ...
... after valve re-replacement for bioprostheses is not well-documented. This research compares the late fate of these two valve ... The fate of bioprostheses (BP) and mechanical prostheses (MP) ... BACKGROUND: The fate of bioprostheses (BP) and mechanical ... Bioprosthesis* / adverse effects. Heart Valve Prosthesis* / adverse effects, classification. Heart Valve Prosthesis ... Next Document: Results of aortic valve replacement with a new supra-annular pericardial stented bioprosthesis.. ...
In this report, the global Vascular Bioprostheses market is valued... ... 103 Pages Report] Check for Discount on Global Vascular Bioprostheses Market Research Report 2018 report by QYResearch Group. ... 1 Vascular Bioprostheses Market Overview. 1.1 Product Overview and Scope of Vascular Bioprostheses. 1.2 Vascular Bioprostheses ... Global Vascular Bioprostheses Market Research Report 2018 Table of Contents. Global Vascular Bioprostheses Market Research ...
Percutaneous Aortic CoreValve Prosthesis in a Degenerated Bioprosthesis Prótesis aórtica percutánea CoreValve sobre prótesis ... We report the first case of successful treatment of severe stenosis of a degenerated aortic bioprosthesis using the ... Carpentier-Edwards bioprosthesis) in 2005 to treat aortic stenosis, presented with symptoms of heart failure. Transthoracic and ...
The ATS 3f Aortic Bioprosthesis is the Companys first entry into ... The ATS 3f Aortic Bioprosthesis is the only tissue valve ... that pre...,ATS,Medical,Announces,First,Commercial,Implants,of,the,ATS,3f,Aortic,Bioprosthesis,in,the,United,States,medicine, ... The ATS 3f Aortic Bioprosthesis is the Companys first entry into ... The ATS 3f Aortic Bioprosthesis is the only tissue valve ... The ATS 3f Aortic Bioprosthesis is the Companys first entry into the $400-plus million U.S. tissue valve market. Based on the ...
A Case of Acute Aortic Regurgitation due to Leaflet Dehiscence of a Carpentier-Edwards Pericardial Bioprosthesis 16 Years after ... A 39-year-old woman, who had undergone aortic valve replacement with a Carpentier-Edwards pericardial bioprosthesis 16 years ...
aortic regurgitation, aortic stenosis, bovine pericardial bioprosthesis, surgical aortic valve replacement Persistent URL. dx. ... One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. Publication. Publication. The ... One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. The Journal of Thoracic and ...
Stentless porcine bioprostheses in the treatment of aortic valve infective endocarditis ... Stentless porcine bioprostheses in the treatment of aortic valve infective endocarditis. Stentless porcine bioprostheses in the ... Stentless aortic bioprostheses: their role in the treatment of aortic endocarditis should not be underestimated. European ... Stentless bioprostheses: a versatile and durable solution in extensive aortic valve endocarditis. European Journal of Cardio- ...
Reoperation of degenerated bioprostheses has a high mortality risk that increases with the age and associated comorbidities of ... Successful Transapical Transcatheter Valve Implantation Within a Dysfunctional Mitral Bioprosthesis. Arend de Weger, Giuseppe ... Successful Transapical Transcatheter Valve Implantation Within a Dysfunctional Mitral Bioprosthesis. Arend de Weger, Giuseppe ... During the procedure, due to the absence of a radiopaque annular ring, the mitral bioprosthesis was only visible on fluoroscopy ...
In February 2011, a number of Russian researchers announced plans to create an artificial human body controlled by a neurointerface by the year 2045.
45.1%). The degree of oversizing for all mechanisms of bioprosthesis failure was 9 ± 10% for stentless ViV-TAVR vs. 6 ± 9% for ... Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses ... Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses ... Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses ...
Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards ... Prospective randomised trial of stented versus stentless bioprosthesis for aortic valve replacement (AVR). ...
Bioprosthesis, Heart valve prosthesis, Multidetector-row computed tomography Persistent URL. dx.doi.org/10.1007/s00330-019- ... Key Points: • Deformation of surgically implanted aortic valve bioprostheses (bio-sAVRs) can be adequately assessed using MDCT ... Surgically implanted aortic valve bioprostheses deform after implantation: insights from computed tomography. Publication. ... Surgically implanted aortic valve bioprostheses deform after implantation: insights from computed tomography. European ...
Aortic and mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: mid-term clinical results. ... durability of this valve is excellent and consider the Carpentier-Edwards pericardial valve as the stented bioprosthesis of ...
  • The objective of this clinical study is to evaluate, at six and twelve months, the hemodynamic performance of the HancockÒ Ultra™ bioprosthesis in the aortic position, to analyze the incidence of patient prosthesis mismatch, correlation of gradients, and to ascertain frequency at which a larger valve size is used vs. a patient's debrided annulus diameter. (clinicaltrials.gov)
  • The primary objective of the study is the hemodynamic performance of the bioprosthesis at 6 and 12 months after surgery. (clinicaltrials.gov)
  • Objectives This study was undertaken to compare the hemodynamic performance of a percutaneous bioprosthesis to that of surgically implanted (stented and stentless) bioprostheses for the treatment of severe aortic stenosis. (onlinejacc.org)
  • Conclusions PAVI provided superior hemodynamic performance compared with the surgical bioprostheses in terms of transprosthetic gradient and prevention of severe prosthesis-patient mismatch, but was associated with a higher incidence of AR. (onlinejacc.org)
  • This prospective observation shows that the NVT Allegra bioprosthesis was associated with a satisfactory safety profile and a remarkable hemodynamic performance after implantation. (viamedica.pl)
  • Pericardial bioprosthesis combine an excellent hemodynamic performance with low thrombogenicity, but valve failure associated with calcification remains a concern with these valves. (biomedcentral.com)
  • The orifice area of mitral bioprostheses provides important information regarding their hemodynamic performance. (biomedcentral.com)
  • The study objectives were to evaluate the safety, efficacy, and hemodynamic performance of a novel stented bovine pericardial aortic valve bioprosthesis 2 years after implantation. (iscts.org.il)
  • Aortic valve replacement with Perceval bioprosthesis is a safe and feasible procedure associated with low mortality and excellent hemodynamic performance. (lww.com)
  • The aim of this prospective, randomized study was to compare the hemodynamic performance of the Medtronic Mosaic and Edwards Perimount bioprostheses in the aortic position, and to evaluate prosthesis-specific differences in valve sizing and valve-size labeling. (qxmd.com)
  • Hemodynamic performance and incidence of patient-prosthesis mismatch of the complete supraannular perimount magna bioprosthesis in the aortic position. (qxmd.com)
  • Hemodynamic performance of the new St. Jude Medical Epic Supra porcine bioprosthesis in comparison to the Medtronic Mosaic on the basis of patient annulus diameter. (qxmd.com)
  • Methods and Results- The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial post commercial clinical transcatheter aortic valve implantation results of the Edwards SAPIEN valve in consecutive patients in Europe. (ahajournals.org)
  • Methods Unadjusted outcome data were collected from the VIVID (Valve-in-Valve International Data) registry between 2007 and 2016 from a total of 1,598 aortic ViV procedures (291 stentless, 1,307 stented bioprostheses). (onlinejacc.org)
  • Methods Medtronic Intact and Carpentier-Edwards Standard (CES), and four contemporary bioprostheses, including one self-expanding prosthesis, were tested with three sonomicrometry probes per valve fixed at commissure attachment points. (rsu.lv)
  • METHODS: Patients with symptomatic degeneration of surgical aortic bioprostheses at high risk (≥50% major morbidity or mortality) for reoperative surgery were prospectively enrolled in the multicenter PARTNER (Placement of Aortic Transcatheter Valves) 2 VIV trial and continued access registries. (blogspot.com)
  • Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards Lifesciences). (isrctn.com)
  • Structural Valve Deterioration in Mitral Replacement Surgery: Comparison of Carpentier-Edwards Supra-Annular Porcine and PERIMOUNT Pericardial Bioprostheses. (edwards.com)
  • Carpentier-Edwards PERIMOUNT pericardial bioprosthesis 16-year results. (edwards.com)
  • The Carpentier-Edwards aortic pericardial valve portfolio is built upon the PERIMOUNT bioprosthesis design. (edwards.com)
  • The Carpentier-Edwards PERIMOUNT Magna Ease pericardial aortic bioprosthesis is intended for use in patients whose aortic valvular disease is sufficiently advanced to warrant replacement of their natural valve with a prosthetic one. (edwards.com)
  • Carpentier-Edwards PERIMOUNT pericardial aortic bioprosthesis. (edwards.com)
  • Between August 2000 and September 2002, 139 patients underwent isolated aortic valve replacement (AVR) with the Mosaic (n = 67) or Perimount (n = 72) bioprosthesis. (qxmd.com)
  • A 39-year-old woman, who had undergone aortic valve replacement with a Carpentier-Edwards pericardial bioprosthesis 16 years previously, was admitted to our hospital with a diagnosis of acute heart failure due to acute aortic regurgitation. (umin.ac.jp)
  • The aortic Carpentier-Edwards pericardial bioprosthesis offers good long-term clinical outcomes with a low rate of structural deterioration. (elsevier.com)
  • Aortic and mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 10-year results. (edwards.com)
  • 15-year experience with the Carpentier-Edwards pericardial bioprosthesis. (edwards.com)
  • Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: a 12-year experience. (edwards.com)
  • Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25 year follow-up of 450 implantations. (edwards.com)
  • Also, it's possible that many patients in the Brazilian trial received their bioprosthesis because of rheumatic valvular disease. (medscape.com)
  • In a prospective echocardiographic study of 150 patients, the author studied aortic root dimensions in patients receiving the ATS 3f(R) Aortic Bioprosthesis with its single suture line/3 tab fixation, stentless valves implanted with conventional double suture line techniques and native valve aortic roots. (emaxhealth.com)
  • The purpose of this study is in an observational design to assess the frequency of subclinical abnormal leaflet motion and morphology in patients treated with transcatheter or surgical aortic valve bioprosthesis. (clinicaltrials.gov)
  • The Toronto Root bioprosthesis with BiLinx anticalcification treatment (St. Jude Medical, St. Paul, MN) was introduced into clinical practice in 2001, mainly for patients with aortic valve disease and additional pathology of the aorta. (ovid.com)
  • A total of 186 patients (62 ± 11 years, 38 female) received full root replacement at our institution with the Toronto Root bioprosthesis from June 2001 until November 2007. (ovid.com)
  • Echocardiographic parameters and other current parameters analyzed in SVD patients such as bioprosthesis calcium scoring derived from CT will be compared to 18F-Fluoride activity. (clinicaltrials.gov)
  • Enter details about all patients having transapical transcatheter mitral valve‑in‑valve implantation for a failed surgically implanted mitral valve bioprosthesis onto the National Institute for Cardiovascular Outcomes Research database (NICOR) and review local clinical outcomes. (nice.org.uk)
  • Reoperation of degenerated bioprostheses has a high mortality risk that increases with the age and associated comorbidities of the patients. (onlinejacc.org)
  • Background Valve-in-valve (ViV) transcatheter aortic replacement (TAVR) is an alternative to redo surgery for patients with a failing aortic bioprosthesis. (onlinejacc.org)
  • This case illustrates the feasibility of tricuspid valve-in-valve procedures in selected patients with large failed tricuspid bioprostheses. (deepdyve.com)
  • Two main types of bioprostheses, stented and stentless valves, are currently used for SAVR with excellent hemodynamic results in the vast majority of patients. (onlinejacc.org)
  • RESULTS From a total sample of 397 patients with the FS and 525 TF bioprostheses with a median follow-up time of 4.0 (2.2-6.0) and 2.4 (1.4-3.7) years, respectively, a matched sample of 329 pairs was obtained. (deepdyve.com)
  • Patients with TF bioprostheses had higher rates of prolonged mechanical ventilation, whereas patients with the FS bioprosthesis showed higher rates of thrombocytopenia. (deepdyve.com)
  • Bioprostheses are the mainstay of aortic valve replacement (AVR) in elderly persons, but their use is increasing in younger patients as well [1]. (deepdyve.com)
  • All patients undergoing aortic (AVR, n = 196), mitral (MVR, n = 502), and mitral-aortic (MAVR, n = 71) valve replacement with a standard Hancock porcine bioprosthesis (HPB) from 1970 to 1983 were reviewed. (mysciencework.com)
  • The aim of the NAUTILUS study was to investigate the safety and performance of the New Valve Technology (NVT) Allegra bioprosthesis in high-risk patients undergoing TAVI. (viamedica.pl)
  • 27 patients with severe, symptomatic AS at high surgical risk were prospectively enrolled, who underwent treatment using the novel self-expanding NVT Allegra bioprosthesis via transfemoral approach (TF-TAVI). (viamedica.pl)
  • Accelerated deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). (medtronic.com)
  • Managing degenerative aortic bioprosthesis with Valve -in-Valve implantation in High risk patients. (incathlab.com)
  • To evaluate the clinical and echocardiographic outcomes in aortic valve replacement (AVR) patients with aortic bioprosthesis under oral anticoagulation (OA). (bjcvs.org)
  • This is mainly due to the improvement in bioprosthesis durability as well as the increased tendency to operate on elderly patients. (bjcvs.org)
  • The aim of our study was to evaluate the clinical and echocardiographic outcomes of patients with aortic bioprosthesis with and without OA. (bjcvs.org)
  • This is a prospective cohort-based study in which we included patients who underwent AVR and received a bioprosthesis from January 2013 until December 2016. (bjcvs.org)
  • A total of 510 patients over the age of 70 years underwent isolated aortic valve replacement with the Mitroflow (A12) pericardial bioprosthesis. (biomedcentral.com)
  • A 64 Multidetector Computed Tomography (MDCT) with retrospective ECG gating study was performed in four patients to evaluate the aortic bioprosthesis. (biomedcentral.com)
  • Chest radiography showed in all patients an irregular bioprosthesis ring. (biomedcentral.com)
  • At preoperative coronary angiography a distorted bioprosthesis ring was detected in all patients. (biomedcentral.com)
  • Demographic data at time of reoperation are listed in Table 1 and the size of the bioprosthesis in Table 2 To date 32 patients (6,2%) have undergone a second aortic valve replacement due to structural valve dysfunction (SVD) resulting from valve calcification. (biomedcentral.com)
  • In two patients the study was performed three weeks after aortic valve replacement with the Mitroflow A12 pericardial bioprosthesis. (biomedcentral.com)
  • Another two patients had bioprosthesis with SVD. (biomedcentral.com)
  • Chest radiography (Figure 1 ) showed in all patients an irregular, non- circular bioprosthesis ring. (biomedcentral.com)
  • Thus, the authors consider relevant to determine the contemporary incidence of thromboembolic events in rheumatic patients early after implantation of aortic and mitral bioprosthesis replacement (first 90 days in the post-operative period) and perform a comparison between isolated Aspirin uses versus no-antiplatelet therapy , in this same context. (bvsalud.org)
  • Between the period of January 2010 to July 2012, all consecutive rheumatic patients , with basal sinus rhythm, who performed mitral and aortic valve replacement with bioprosthesis (pericardial bovine), were included in this prospective cohort study , 184 patients in total. (bvsalud.org)
  • Between 1996 and 2003, 587 patients (mean 75 years) underwent AVR with stentless Medtronic Freestyle ® bioprostheses. (biomedcentral.com)
  • Sutureless bioprostheses have shown benefits in high- risk patients , such as reduction of aortic clamping and cardiopulmonary bypass , decreasing risks and adverse effects . (bvsalud.org)
  • The deployment of the sutureless bioprosthesis was safe and effective, thereby representing a new alternative to conventional surgery or transcatheter in moderate- to high- risk patients with severe aortic stenosis . (bvsalud.org)
  • Between March 2011 and January 2015, 517 patients underwent AVR with Perceval bioprosthesis. (lww.com)
  • The reoperation rate was 12.1% in the bioprosthetic valve group at 15 years and 6.9% in the mechanical valve group, while major bleeding occurred in 6.6% of bioprosthesis patients and in 13.0% of the mechanical-valve group. (medscape.com)
  • Influence of completely supra-annular placement of bioprostheses on exercise hemodynamics in patients with a small aortic annulus. (qxmd.com)
  • Hemodynamic comparison of bioprostheses for complete supra-annular position in patients with small aortic annulus. (qxmd.com)
  • Multicenter evaluation of the bovine mesenteric vein bioprostheses for hemodialysis access in patients with an earlier failed prosthetic graft. (duke.edu)
  • This report evaluates use of mesenteric vein bioprosthesis (MVB) as a conduit for patients who have failed at least one earlier synthetic vascular access graft. (duke.edu)
  • Although TAVI in patients with degenerated surgical aortic bioprostheses (i.e. valve-in-valve TAVI) is increasingly reported in Western studies, such data is lacking in Asian patients. (smj.org.sg)
  • Eight patients who underwent valve-in-valve TAVI due to degenerated aortic bioprostheses were enrolled. (smj.org.sg)
  • 3 , 4 ) Due to the minimally invasive nature of the technique, valve-in-valve TAVI is increasingly used as an alternative treatment modality in patients with degenerated surgical bioprostheses in the aortic position. (smj.org.sg)
  • Eight consecutive patients who underwent valve-in-valve TAVI in a single centre due to degenerated surgical bioprostheses in the aortic position were included in the study. (smj.org.sg)
  • The 50 bioprostheses of this study were explanted from 25 patients reoperated on because of malfunctioning due to primary tissue failure. (elsevier.com)
  • During the selection of the appropriate Edwards-Sapien valve size (Edwards Lifesciences Inc., Irvine, California), the internal diameter and length of the pre-existing mitral bioprosthesis using multiplanar reconstructions by 320-row MDCT were taken into consideration ( Fig. 1 B). Because the 27-mm Medtronic Mosaic bioprosthetic valve (Medtronic Inc.) had an internal diameter of 24 mm, a 26-mm Edwards-Sapien valve prosthesis (Edwards Lifesciences Inc.) was selected. (onlinejacc.org)
  • With 320-row MDCT, a circular deployment of the 26-mm Edwards-Sapien valve (Edwards Lifesciences Inc.) within the bioprosthetic mitral valve was demonstrated ( Fig. 1 G). This case illustrates the feasibility of using a transcatheter valve-in-valve procedure in a dysfunctional mitral bioprosthesis and the role of multimodality imaging to accurately select the prosthesis and to guide the procedure. (onlinejacc.org)
  • We report the first case of implantation of an Edwards SAPIEN XT transcatheter heart valve (Edwards Lifesciences, Irvine, California) in the native pulmonary valve position through a tricuspid valve bioprosthesis to treat severe pulmonary valve regurgitation as a result of carcinoid heart disease. (onlinejacc.org)
  • After a multidisciplinary team discussion, the patient underwent end-to-side grafting of the left internal mammary artery onto the left anterior descending coronary artery and placement of a 25-mm Carpentier-Edwards bioprosthesis (Edwards Lifesciences) in the tricuspid position. (onlinejacc.org)
  • The major players covered in Bioprosthesis Valves are: Edwards Lifesciences Corporation Valcare Medical Medtronic LivaNova Pulmonx Meril Life Sciences Braile Biomedica Affluent Medical Labcor Irvine Center Drive Colibri Heart Valve Among other players domestic and global, Bioprosthesis Valves market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. (globalinforesearch.com)
  • 1.1 The current evidence on the safety of transapical transcatheter mitral valve‑in‑valve implantation for a failed surgically implanted mitral valve bioprosthesis shows the potential for serious complications. (nice.org.uk)
  • 1.4 Transapical transcatheter mitral valve‑in‑valve implantation for a failed surgically implanted mitral valve bioprosthesis should only be done by clinicians and teams with special training and experience in complex endovascular cardiac interventions, including regular experience in transcatheter valve implantation procedures. (nice.org.uk)
  • 1.5 NICE encourages further research into transapical transcatheter mitral valve‑in‑valve implantation for a failed surgically implanted mitral valve bioprosthesis. (nice.org.uk)
  • Deformation of surgically implanted aortic valve bioprostheses (bio-sAVRs) can be adequately assessed using MDCT. (eur.nl)
  • Hydraulic characteristics of heart valve bioprostheses mounted on supporting structures of various rigidity have been studied under physiologic conditions. (worldwidescience.org)
  • Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis. (biomedsearch.com)
  • We report the first case of successful treatment of severe stenosis of a degenerated aortic bioprosthesis using the percutaneous CoreValve prosthesis. (revespcardiol.org)
  • We describe the first case series of valve-in-valve TAVI for degenerated aortic surgical bioprostheses in Asia. (smj.org.sg)
  • He underwent an aortic valve replacement with a Freedom SOLO bioprosthesis 6 years ago. (worldwidescience.org)
  • A 60-year-old man with hepatic cirrhosis and portal hypertension, who underwent aortic valve replacement (Carpentier-Edwards bioprosthesis) in 2005 to treat aortic stenosis, presented with symptoms of heart failure. (revespcardiol.org)
  • A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. (google.co.uk)
  • The ATS 3f Aortic Bioprosthesis is the only tissue valve that pre. (bio-medicine.org)
  • The ATS 3f Aortic Bioprosthesis is the Company's first entry into the $400-plus million U.S. tissue valve market. (bio-medicine.org)
  • Based on the precept that 'Form Follows Function', the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve. (bio-medicine.org)
  • The ATS 3f Aortic Bioprosthesis is the only tissue valve that preserves the sinuses and restores native valve stress distribution and physiologic flow to the entire aortic root," commented Dr. Stewart. (bio-medicine.org)
  • By Type, Bioprosthesis Valves market has been segmented into Porcine Tissue Bovine Tissue By Application, Bioprosthesis Valves has been segmented into: Hospitals Clinics Others Regions and Countries Level Analysis Regional analysis is another highly comprehensive part of the research and analysis study of the global Bioprosthesis Valves market presented in the report. (globalinforesearch.com)
  • We have analyzed the tissue failure phenomenon in mitral and aortic porcine bioprostheses explanted from the same patient so as to avoid the bias of host factors. (elsevier.com)
  • In this category we find examples such as animal tissue prostheses (xenogeneic bioprosthesis). (wikipedia.org)
  • We describe the first report of an Edwards SAPIEN valve implanted in a tricuspid bioprosthesis from the femoral vein. (worldwidescience.org)
  • After failed aggressive medical therapy and surgical turn down, an Edwards SAPIEN XT valve was deployed in the tricuspid bioprosthesis via the right femoral vein. (worldwidescience.org)
  • Transfemoral venous access was obtained, and the tricuspid valve bioprosthesis was crossed with a balloon-tipped pulmonary artery catheter. (onlinejacc.org)
  • This was followed by direct implantation of a 26-mm Edwards SAPIEN XT valve in the pulmonic position, which resulted in an excellent angiographic appearance with trivial catheter-induced pulmonary regurgitation and a well-functioning tricuspid valve bioprosthesis ( Figure 3 Online Video 3 ). (onlinejacc.org)
  • We report a case of a transcatheter tricuspid valve-in-valve implantation with a 29-mm balloon-expandable prosthesis within a 33-mm failed bioprosthesis (exceeding manufacturer's sizing recommendations). (deepdyve.com)
  • The Porcine Organic Valvular Bioprosthesis is indicated for mitral, aortic, tricuspid or pulmonary valve replacements. (medicalexpo.com)
  • The NaviGate bioprosthesis is a novel self-expanding valved stent designed to treat functional tricuspid regurgitation. (onlinejacc.org)
  • A new CEP bioprosthesis was implanted in the mitral position. (worldwidescience.org)
  • Based on these experiences with aortic bioprostheses, and on the established application of CMR to assess the severity of native mitral stenosis [ 4 , 5 ], it would be desirable to apply this method to bioprostheses implanted in the mitral position. (biomedcentral.com)
  • However, recent clinical experience has suggested that subclinical aortic valve bioprosthesis thrombosis may occur early after valve replacement. (clinicaltrials.gov)
  • The Toronto Root bioprosthesis is safe and provides good clinical and hemodynamic function after full root replacement with or without additional aortic surgery. (ovid.com)
  • With more than six years of clinical experience confirming excellent safety and efficacy, the demonstrated clinical benefit and recent FDA approval of the ATS 3f Aortic Bioprosthesis are creating excitement and product demand among U.S. surgeons. (bio-medicine.org)
  • The main goal of the present study was to compare the mid-term clinical outcomes and short-term haemodynamic performances of stentless FS and stented TF bioprostheses. (deepdyve.com)
  • The objective of this study was to experimentally evaluate the implantation of a novel balloon-expandable aortic valve with sutureless bioprosthesis in sheep and report the early clinical application. (bvsalud.org)
  • Is the degeneration of aortic valve bioprostheses similar to that of native aortic valves? (nih.gov)
  • Mean duration to surgical bioprosthesis degeneration was 10.2 ± 4.1 years. (smj.org.sg)
  • There was a possible relationship between early bioprosthetic calcification and radiologic distortion of the bioprosthesis ring. (biomedcentral.com)
  • The Complete Supraannular Concept, In Vivo Hemodynamics of Bovine and Porcine Aortic Bioprostheses. (edwards.com)
  • A Carpentier-Edwards pericardial (CEP) bioprosthesis was explanted from an 81-year-old woman due to nonstructural dysfunction 9 years after mitral valve replacement. (worldwidescience.org)
  • Transesophageal echocardiography revealed severe mitral regurgitation secondary to a degenerative flail bioprosthesis ( Fig. 1 A). The patient's logistic EuroSCORE was 32% for repeat mitral valve operation. (onlinejacc.org)
  • The study sought to assess outcomes of transcatheter mitral valve-in-valve implantation (TMVIV) for degenerated bioprostheses and transcatheter mitral valve-in-ring implantation (TMVIR) for failed annuloplasty rings according to access route and the Mitral Valve Academic Research Consortium (MVARC) criteria. (eurekamag.com)
  • In conclusion, the new mitral bioprosthesis provide excellent in vivo performance that mimics the native mitral valve. (elsevier.com)
  • The Avalus bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. (medtronic.com)
  • These 2 bovine pericardial bioprostheses have been widely adopted at most centres and we aimed to compare TF with FS, the most recently available models of their respective counterparts. (deepdyve.com)
  • Sorin's (now LivaNova) Freedom Solo® (FS) bioprosthesis is the latest evolution of pericardial stentless valves with a simplified, faster implantation procedure compared with other stentless valves [2-4]. (deepdyve.com)
  • The valve is placed in the supra-annular position compared with the intra-annular position in some of the other bioprostheses. (ahajournals.org)
  • Results of aortic valve replacement with a new supra-annular pericardial stented bioprosthesis. (biomedsearch.com)
  • The Toronto root stentless valve in the subcoronary position is hemodynamically superior to the mosaic stented completely supra-annular bioprosthesis. (qxmd.com)
  • Results An increase in radius by 7.3 ± 2.6, 8.7 ± 0.0 and 3.9 ± 0.0% for the porcine aortic root, CES and Intact valves, respectively, was observed during transition from diastolic to systolic pressure and less for contemporary bioprostheses-mean 2.5 ± 0.9%, lowest 1.2 ± 0.0. (rsu.lv)
  • Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience. (nih.gov)
  • We conclude that the mid-term durability of this valve is excellent and consider the Carpentier-Edwards pericardial valve as the stented bioprosthesis of choice both in the aortic and mitral positions for the elderly. (kuleuven.be)
  • Postoperative outcomes and survival rates were comparable for both bioprostheses. (deepdyve.com)
  • The sutureless bioprosthesis was deployed to the aortic valve , with 1/3 of the structure on the left ventricular face . (bvsalud.org)
  • We describe our experience with sutureless Perceval (Sorin Group, Italy) aortic bioprosthesis. (lww.com)
  • Ministernotomy implant of Sorin Perceval S Sutureless Bioprosthesis, by courtesy of Livanova, London. (springer.com)
  • 6.40: Sorin Perceval S sutureless bioprosthesis collapsing procedure. (springer.com)
  • n=17) or stenosis (n=7) using balloon-expandable bioprostheses. (eurekamag.com)
  • We have developed a surgical technique by which we were able to ameliorate this troublesome situation in a 79-year-old man with aortic stenosis in whom we had to intraoperatively explant the bioprosthesis that we have put in initially. (elsevier.com)
  • The bioprosthesis was initially implanted in an 85 year-old patient with aortic stenosis and high risk for conventional surgery , EuroSCORE 40 and multiple comorbidities. (bvsalud.org)
  • Objectives Little is known about the stent deformability required for optimal stented heart valve bioprosthesis design. (rsu.lv)
  • Stent mounted bioprostheses were prepared either sequentially as previously described or differentially with AlCl 3 exposure restricted to the aortic wall followed by ethanol pretreatment. (elsevier.com)
  • Since the rigid stent is considered to be incremented in these disadvantages, stentless bioprostheses were developed. (biomedcentral.com)
  • We report a case of deceleration injury causing traumatic dehiscence of a Medtronic Freestyle aortic bioprosthesis (Medtronic Inc, Minneapolis, MN) in a 70-year-old patient 5 years after a total root reconstruction. (elsevier.com)
  • What prosthesis should be used at valve re-replacement after structural valve deterioration of a bioprosthesis? (biomedsearch.com)
  • This research compares the late fate of these two valve types after valve re-replacement for structural valve deterioration (SVD) of a bioprosthesis. (biomedsearch.com)
  • Erdem, CC & Park, SJ 2009, ' A smart method of intraoperative explantation of an aortic bioprosthesis ', Journal of Cardiac Surgery , vol. 24, no. 5, pp. 515-517. (elsevier.com)
  • In this study, we further evaluated its in vivo performance by intraoperative epicardial Echo/Doppler immediately after the bioprosthesis was implanted in 10 sheep. (elsevier.com)
  • We describe for the first time a valve-in-valve procedure with a CoreValve prosthesis for the treatment of a severely stenotic degenerated aortic bioprosthesis. (biomedsearch.com)
  • Asmarats, Luis;Houde, Christine;Pasian, Sergio;Rodés-Cabau, Josep 2018-03-01 00:00:00 Abstract Transcatheter valve-in-valve implantation within dysfunctional surgical bioprosthesis has become an alternative to redo open-heart surgery. (deepdyve.com)
  • Σφακιανάκης: Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry. (blogspot.com)
  • To our knowledge, this is the third failure of a Freedom SOLO bioprosthesis reported in the literature. (worldwidescience.org)
  • When the long-term follow-up of the Freedom SOLO bioprosthesis is available, it has to be compared with other bioprosthesis for long-term durability. (worldwidescience.org)
  • The stentless Freedom Solo aortic bioprosthesis is implanted supraannularly using one running suture line in the sinuses of Valsalva. (worldwidescience.org)
  • St. Jude's (now Abbott) Trifecta® (TF) is a new stented bioprosthesis with externally mounted pericardial leaflets that allow for theoretical optimization of effective orifice area (EOA). (deepdyve.com)
  • The bioprosthesis is made of a metal frame and bovine pericardium leaflets, encapsulated in a catheter . (bvsalud.org)
  • The global Bioprosthesis Valves market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of XX%% in the forecast period of 2020 to 2025 and will expected to reach USD XX million by 2025, from USD XX million in 2019. (globalinforesearch.com)
  • For the period 2015-2020, this study provides the Bioprosthesis Valves sales, revenue and market share for each player covered in this report. (globalinforesearch.com)
  • Chapter 4, the Bioprosthesis Valves breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020. (globalinforesearch.com)
  • The standard Hancock porcine bioprosthesis: overall experience. (mysciencework.com)
  • The Hancock M.O. II aortic bioprosthesis (porcine). (medscape.com)
  • INTRODUCTION This booklet provides guidelines for the handling and implantation of the Mosaic ® and Hancock ® II bioprostheses. (sputtr.com)
  • Another bioprosthesis of the same kind was used to replace the old prosthesis with the rest of his postoperative course until dismissal being eventless. (elsevier.com)
  • There is still much debate regarding the kind of antithrombotic therapy in the immediate postoperative period of bioprosthesis replacement (first three months). (bvsalud.org)
  • We studied systematically the role of surgeons and other possible determinants for mid-term survival, postoperative gradients and Quality of Life (QoL) after aortic valve replacement (AVR) with Freestyle ® stentless bioprostheses. (biomedcentral.com)
  • Cardiovascular magnetic resonance (CMR) has been proven as an accurate alternative for assessing aortic bioprostheses. (biomedcentral.com)
  • Recently, cardiovascular magnetic resonance (CMR) has been identified as an accurate non-invasive tool for the assessment of the orifice area of bioprostheses implanted in the aortic position. (biomedcentral.com)
  • La misión de la Sociedad Española de Cirugía Torácica y Cardiovascular es asegurar la calidad en el ejercicio de las cirugías torácica y cardiovascular mediante la formación, la promoción de la investigación, el desarrollo y difusión de estándares y guías, y su influencia sobre las políticas sanitarias a nivel nacional. (elsevier.es)
  • Leaflet immobility and valve thrombosis have been reported with both transcatheter and surgical aortic valve bioprostheses. (elsevier.com)